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Table 1
Recommended Adult Immunization Schedule





Table 2
The Medical Indications Schedule




Notes 
Special situations
• Chronic liver disease (e.g., persons with hepatitis B, hepatitis C, cirrhosis, fatty liver disease, alcoholic liver disease, 
autoimmune hepatitis, and an alanine aminotransferase [ALT] or aspartate aminotransferase [AST] level greater than twice 
the upper limit of normal)
• HIV infection
• Settings for exposure, including health care settings targeting services to injection or noninjection drug users or group 
homes and nonresidential day care facilities for developmentally disabled persons (individual risk factor screening not 
required)
• Removal of clotting factor disorders as an indication
Routine vaccination
• HPV vaccination recommended for all adults through 
age 26 years: 2- or 3-dose series depending on age at 
initial vaccination or condition
Shared Clinical Decision-Making
• Age 27-45 years based on shared clinical decision-
making: 2- or 3-dose series as above
Special Situations
• LAIV should not be used in persons with the following conditions or situations:
• History of severe allergic reaction to any vaccine component (excluding egg, 
see above) or to a previous dose of any influenza vaccine
• Immunocompromised due to any cause (including medications and HIV 
infection)
• Anatomic or functional asplenia
• Cochlear implant
• Cerebrospinal fluid-oropharyngeal communication
• Close contacts or caregivers of severely immunosuppressed persons who 
require a protective environment
• Pregnancy
• Received influenza antiviral medications within the previous 48 hours
• History of Guillain-Barré syndrome within 6 weeks of previous dose of influenza 
vaccine: Generally should not be vaccinated unless vaccination benefits outweigh risks 
for those at higher risk for severe complications from influenza
Special Situations
• Health care personnel:
• Born in 1957 or later with no evidence of immunity to 
measles, mumps or rubella: 2-dose series at least 4 weeks 
apart for measles or mumps, or at least 1 dose for rubella
• Born before 1957 with no evidence of immunity to measles, 
mumps or rubella: Consider 2-dose series at least 4 weeks 
apart for measles or mumps, or 1 dose for rubella
Shared Clinical Decision-Making for MenB
• Adolescents and young adults age 16 through 23 
years (age 16 through 18 years preferred) not at 
increased risk for meningococcal disease: Based 
on shared clinical decision-making, 2-dose series 
MenB-4C at least 1 month apart or 2-dose series 
MenB-FHbp at 0, 6 months
Routine vaccination
• Only 1 dose PPSV23 should be administered on or after the 65th birthday
Shared Clinical Decision-Making
• Age 65 years or older (immunocompetent): 1 dose PCV13 is recommended based 
on shared clinical decision-making.
• PCV13 and PPSV23 should not be administered during the same visit
• If both PCV13 and PPSV23 are to be given, PCV13 should be administered 
first
• PCV13 and PPSV23 should be administered at least 1 year apart. PPSV23 
should be given at least 5 years after any previous PPSV23 dose
Routine vaccination
• Previously did not receive Tdap at or 
after age 11 years: 1 dose Tdap, then 
Td or Tdap every 10 years
Special situations
• Previously did not receive primary vaccination series 
for tetanus, diphtheria, and pertussis: At least 1 dose 
Tdap followed by 1 dose Td or Tdap at least 4 weeks 
after Tdap and another dose Td or Tdap 6–12 months 
after last Td or Tdap (Tdap can be substituted for any Td 
dose, but preferred as the first dose); Td or Tdap every 
10 years thereafter
• For information on use of Td or Tdap as tetanus 
prophylaxis in wound management, see 
https://www.cdc.gov/mmwr/volumes/67/rr/rr6702a1.
htm
Special situations
• HIV infection with CD4 count ≥200 cells/µL with no 
evidence of immunity: Vaccination may be considered 
(2 doses, administered 3 months apart)
Discussion
